 "Govt says Covid-19 drug Remdesivir will sell at set price, ups production")
The Centre has decided to increase production of anti-viral drug Remdesivir and it will be provided to people at government's price, said Union Minister Nitin Gadkari on Thursday.
This comes after several cases of blackmarketing of Remdesivir came to light amid the COVID-19.
"There was a shortage of Remdesivir injection. Because of this, incidents of black marketing took place, several people lost their lives as they have not received Remdesivir, so we decided to increase its production," Gadkari said.
"But we tried (and to got manufacturing rights), Remdesivir will be provided to people at government's price. Now, I think there will be no black marketing or no person will die due to lack of it, there is no reservation, can be provided to other states when there will be surplus," he added.
Gadkari on Thursday visited the Genetic Life Sciences (pharmacy) in Wardha to oversee the production of Remdesivir injections.
There are currently 35,66,398 active cases in the country, as per Union Health Ministry.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app